1
1

A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.

4/17/2026, 2:15 PM

Summary of Bill S 4327

The bill titled "A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes," was introduced in the 119th Congress on April 16, 2026. The bill aims to mandate regulatory review processes specifically for pharmaceutical products originating from Chinese entities, likely focusing on ensuring safety, efficacy, and compliance standards for such products.

Current Status of Bill S 4327

Bill S 4327 is currently in the status of Bill Introduced since April 16, 2026. Bill S 4327 was introduced during Congress 119 and was introduced to the Senate on April 16, 2026.  Bill S 4327's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 16, 2026

Bipartisan Support of Bill S 4327

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 4327

Primary Policy Focus

Alternate Title(s) of Bill S 4327

A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.
A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.

Comments